Suberanilohydroxamic acid (SAHA) inhibits collagen deposition in a transforming growth factor β1-driven precision cut lung slice (PCLS) model of pulmonary fibrosis by Brand, Oliver J. et al.
Brand, Oliver J. and Pasini, Alice and Habgood, Antony 
and Knox, Alan J. and Jenkins, Gisli and Pang, Linhua 
(2016) Suberanilohydroxamic acid (SAHA) inhibits 
collagen deposition in a transforming growth factor β1-
driven precision cut lung slice (PCLS) model of 
pulmonary fibrosis. In: British Thoracic Society Winter 
Meeting 2016, 7-9 Dec 2016, London, UK. 
(Unpublished) 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/38772/1/BTS-Abstract-Final.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Suberanilohydroxamic	  Acid	  (SAHA)	  Inhibits	  Collagen	  deposition	  in	  a	  
Transforming	  Growth	  Factor	  β1-­‐driven	  Precision	  Cut	  Lung	  Slice	  (PCLS)	  model	  of	  Pulmonary	  Fibrosis.	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Introduction	  and	  Objectives:	  Idiopathic	  Pulmonary	  Fibrosis	  (IPF)	  is	  a	  chronic,	  progressive	  interstitial	  lung	  
disease	  that	  is	  refractory	  to	  current	  treatment	  options.	  Transforming	  growth	  factor	  (TGF)-­‐β1	  is	  a	  key	  
pro-­‐fibrotic	  cytokine	  that	  plays	  a	  crucial	  role	  in	  IPF	  pathogenesis.	  Our	  group	  previously	  demonstrated	  
distinct	  epigenetic	  modifications	  involved	  in	  repression	  of	  the	  antifibrotic	  gene	  cyclooxygenase-­‐2	  (COX-­‐
2)	  in	  fibroblasts	  from	  IPF	  (F-­‐IPF)	  lungs	  compared	  with	  fibroblasts	  from	  non-­‐fibrotic	  lungs	  (F-­‐NL).	  
Epigenetic	  drugs	  capable	  of	  inhibiting	  DNA	  and	  histone	  modifications	  may,	  therefore,	  represent	  a	  
putative	  novel	  therapy.	  The	  aim	  of	  this	  study	  was	  to	  investigate	  the	  ability	  of	  4	  epigenetic	  inhibitors	  to	  
regulate	  TGF-­‐β-­‐driven	  fibrosis	  in	  ex	  vivo	  mouse	  lung.	  
Methods:	  A	  precision-­‐cut	  lung	  slice	  (PCLS)	  model	  of	  fibrosis	  was	  established	  using	  the	  previously	  
described	  [1]	  CC10-­‐tTS-­‐rtTA-­‐TGFβ1	  transgenic	  (tgTGF-­‐β1)	  mouse.	  The	  model	  was	  first	  assessed	  by	  
investigating	  PCLS	  overexpression	  of	  TGF-­‐β1	  in	  response	  to	  stimulation	  of	  the	  transgene	  by	  doxycycline	  
treatment.	  Gene	  expression	  of	  COX-­‐2	  and	  fibrotic	  markers	  including	  collagen	  were	  assessed	  after	  4	  days	  
of	  treatment.	  The	  anti-­‐fibrotic	  potential	  of	  4	  epigenetic	  inhibitors;	  BIX01294	  (BIX,	  inhibitor	  of	  G9a	  
histone	  methyltransferase),	  3-­‐deazaneplanocin	  A	  (DZNep,	  inhibitor	  of	  EZH2	  histone	  methyltransferase),	  
SAHA	  (inhibitor	  of	  histone	  deacetylases,	  HDACs)	  and	  Decitabine	  (DAC,	  DNA	  demethylating	  agent)	  was	  
investigated.	  Viability	  of	  PCLS	  was	  assessed	  by	  MTT	  and	  Prestoblue®	  viability	  assay.	  
Results:	  Treatment	  of	  PCLS	  from	  tgTGF-­‐β1	  mice	  with	  doxycycline	  induced	  a	  concentration-­‐dependent	  
increase	  in	  global	  TGF-­‐β1,	  pro-­‐fibrotic	  markers	  including	  collagen	  and	  pro-­‐inflammatory	  COX-­‐2,	  which	  
was	  comparable	  to	  recombinant	  TGF-­‐β1	  treatment.	  Treatment	  with	  three	  of	  the	  epigenetic	  inhibitors	  
BIX01294,	  DZNep	  and	  DAC	  did	  not	  reduce	  the	  pro-­‐fibrotic	  response	  following	  doxycycline	  treatment.	  
However	  SAHA	  demonstrated	  a	  significant	  suppressive	  effect	  on	  COX-­‐2	  and	  collagen	  expression,	  while	  
not	  directly	  affecting	  TGF-­‐β1	  transgene	  expression.	  	  
Conclusions:	  The	  data	  suggests	  that	  SAHA	  has	  the	  potential	  to	  reduce	  fibrosis	  in	  a	  TGF-­‐β1	  driven	  model	  
of	  pulmonary	  fibrosis.	  Further	  work	  is	  currently	  underway	  to	  assess	  the	  anti-­‐fibrotic	  potential	  of	  this	  
drug	  in	  tgTGF-­‐β1	  animals.	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